News Archive

13 September 2013

MSD Animal Health Announces Sponsorship of World Tilapia Conference

Company to Also Host Industry Workshop With Leading Tilapia Producers 

BOXMEER, NETHERLANDS, 13 September, 2013 – MSD Animal Health (known as Merck Animal Health in the United States and Canada) announced today its sponsorship of the World Tilapia Conference being held in Rio de Janeiro, Brazil 16-18 Sept. 2013. The conference will bring together experts from across the globe to share insights on the growing tilapia market and discuss how farmers can improve the productivity and sustainability of their operations.

“The growing demand for tilapia makes proper disease control increasingly important,” said Robin Wardle, Aquaculture Director, MSD Animal Health. “MSD Animal Health is committed to providing solutions that can help fish farmers improve disease control and maintain production efficiency.”

On 18 Sept. at 12:30 p.m., key note speaker Rodrigo Zanolo, Aquaculture Manager, MSD Animal Health, Brazil, will discuss the impact that sanitary issues can have on the productivity and sustainability of tilapia culture in a session on sanitary issues and farm certification standards. 

During the conference, MSD Animal Health is also assembling some of the world’s leading tilapia producers for a workshop to discuss global market trends and identify issues that could potentially affect the growth of the industry. The workshop will include a presentation by protein production expert Osler Desouzart, CEO of OD Consulting and a member of the Advisory Board of the World Agriculture Forum.

“Tilapia production has grown significantly over the years, making it one of the most important species in aquaculture,” added Robin Wardle. “We are pleased to support the continued growth and development of tilapia production by taking part in the World Tilapia Conference.”

For more information about the World Tilapia Conference, visit http://infopesca.org/node/955. For more information about MSD Animal Health’s aquaculture business, visit http://aqua.merck-animal-health.com.

About MSD Animal Health
Today's Merck is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of Merck. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.

Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment;  technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).